Compare ADMA Biologics Inc (ADMA) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Schwab US Large Cap Growth ETF — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Schwab US Large Cap Growth ETF trades at $34.19. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SCHG | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $35.30 |
52-Week Low | $7.60 | $28.10 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.53, up 1.2% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides concentrated exposure to large-cap growth stocks, particularly in technology, with top holdings like Nvidia, Apple, and Microsoft. Recent news highlights its positioning to benefit from AI-driven capital expenditure growth, though some analysts note concentration risks.
The outlook for SCHG is supported by strong AI adoption trends and institutional inflows, but risks include high portfolio concentration and sensitivity to interest rate changes. Valuation remains elevated, with a portfolio P/E around 32x, which could pressure returns if growth expectations moderate. Investors should weigh the growth potential against these concentration and macroeconomic risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
